Reaction

Injection Site Inflammation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,878 reports · 76 co-occurring drugs

As of the last recalculation, Injection Site Inflammation appears in 4,878 FAERS reports alongside 76 co-occurring drug terms. The strongest observed disproportionality signal is INTERFERON BETA-1B (PRR 15.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Interferon Beta-1B	69	15.6	15.6
Anakinra	50	13.0	13.0
Fremanezumab-Vfrm	31	11.6	11.6
Peginterferon Beta-1A	34	11.1	11.2
Asfotase Alfa	24	10.3	10.3
Naltrexone	73	10.2	10.3
Glatiramer Acetate	138	10.1	10.1
Ixekizumab	85	10.0	10.0
Testosterone Cypionate	20	9.6	9.6
Pegvaliase-Pqpz	16	8.3	8.3
Methylprednisolone Acetate	15	8.0	8.0
Cabotegravir	15	7.9	8.0
Octreotide Acetate	56	7.9	7.9
Etanercept	805	6.7	6.7
Galcanezumab-Gnlm	39	5.3	5.3
Sarilumab	32	5.2	5.2
Desoximetasone	23	5.2	5.2
Botulinum Toxin Type A	15	5.2	5.2
Inclisiran	9	4.8	4.8
Insulin Glulisine	11	4.6	4.6
Dupilumab	463	4.4	4.4
Quetiapine Fumarate	30	4.4	4.4
Alirocumab	25	4.3	4.3
Azathioprine	85	4.2	4.2
Romosozumab-Aqqg	13	4.1	4.1
Iron Sucrose	9	4.0	4.0
Tirzepatide	141	3.8	3.8
Abaloparatide	26	3.8	3.8
Interferon Beta-1A	159	3.6	3.6
Leflunomide	85	3.5	3.5
Onabotulinumtoxina	62	3.5	3.5
Sulfasalazine	61	3.4	3.4
Medroxyprogesterone Acetate	38	3.3	3.3
Lanreotide Acetate	6	3.3	3.3
Tocilizumab	86	3.3	3.3
Thyroid, Porcine	8	3.2	3.2
Butalbital, Acetaminophen, And Caffeine	8	3.2	3.2
Valacyclovir Hydrochloride	52	3.2	3.2
Nitrofurantoin	12	3.1	3.1
Nitrofurantoin (Monohydrate/Macrocrystals)	12	3.1	3.1
Adalimumab	460	3.0	3.0
Triamcinolone Acetonide	21	2.9	2.9
Hydroxychloroquine	49	2.8	2.8
Leuprolide Acetate	50	2.8	2.8
Doxazosin Mesylate	23	2.7	2.7
Cetirizine Hydrochloride Allergy	19	2.7	2.7
Cetirizine Hydrochloride Tablets	19	2.7	2.7
Valacyclovir	26	2.7	2.7
Ibuprofen Tablets, Coated	26	2.6	2.6
Ibuprofen Sodium	26	2.6	2.6
Fulvestrant	20	2.6	2.6
Paliperidone Palmitate	19	2.5	2.5
Tramadol Hydrochloride	22	2.5	2.5
Exenatide	30	2.4	2.4
Canakinumab	6	2.4	2.4
Aflibercept	17	2.3	2.3
Levocetirizine Dihydrochloride	13	2.3	2.3
Tofacitinib Citrate	7	2.3	2.3
Buprenorphine	48	2.2	2.2
Bimekizumab	11	2.2	2.2
Teriparatide	56	2.1	2.1
Ofatumumab	16	2.1	2.1
Peginterferon Alfa-2A	24	1.9	1.9
Dulaglutide	39	1.9	1.9
Omalizumab	37	1.9	1.9
Abatacept	57	1.8	1.8
Evolocumab	63	1.7	1.7
Certolizumab Pegol	45	1.6	1.6
Azacitidine	11	1.6	1.6
Liraglutide	18	1.6	1.6
Treprostinil	44	1.5	1.5
Belimumab	11	1.5	1.5
Erenumab-Aooe	16	1.2	1.2
Somatropin	17	1.0	1.0
Guselkumab	8	1.0	1.0
Palivizumab	3	0.8	0.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.